AKESO (09926) saw its shares rise by nearly 3%. As of the time of writing, the stock was up 2.66%, trading at HK$150.6 with a turnover of HK$613 million. The increase follows the company's announcement on its official social media account that significant data from the Phase II clinical trial (COMPASSION-26) of its globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with chemotherapy as a first-line treatment for advanced pancreatic cancer (PDAC), was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Study results indicated that the cadonilimab combination regimen demonstrated promising anti-tumor activity and survival benefits in patients with advanced pancreatic cancer. Notably, in patients with locally advanced, inoperable disease, the median overall survival (OS) reached 23.4 months and the median progression-free survival (PFS) reached 11.1 months.